Mylan sues Celgene for blocking Revlimid, Thalomid generics

Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market. The lawsuit accuses Celgene of maintaining unlawful monopolies over Revlimid, which treats disorders caused by poorly formed blood cells; Revlimid is a branded version of lenalidomide, and is a derivative of thalidomide, a drug introduced in the 1950s for which Thalomid is a branded version. Mylan said both drugs can cost more than $100,000 for a year's supply.



via Health News Headlines - Yahoo News http://ift.tt/1pXiGKZ